Targeting Glioma Stem Cells
Yagmur Muftuoglu1, Frank Pajonk2
1Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, 300 Stein Plaza Driveway, Suite 420, Los Angeles, CA 90095-1714, USA.
Neurosurgery Clinics of North America
|March 30, 2021
Summary
Glioma-initiating cells (GICs) drive glioblastoma growth and resistance. Targeting dopamine receptors may improve current therapies against these resilient tumor cells.
Area of Science:
- Neuro-oncology
- Cancer Stem Cell Biology
Background:
- Glioma-initiating cells (GICs) are a small subpopulation crucial for glioblastoma (GBM) propagation, invasion, immune evasion, and therapeutic resistance.
- Understanding GIC heterogeneity is vital for predicting patient outcomes and developing effective treatments.
Purpose of the Study:
- To explore the complex role of GICs in glioblastoma.
- To discuss challenges in GIC characterization and therapeutic targeting.
- To introduce dopamine receptor antagonists as a potential therapeutic strategy.
Main Methods:
- Review of current literature on GIC biology and glioblastoma.
- Discussion of challenges in GIC subpopulation analysis.
- Introduction of pharmacological agents targeting dopamine receptors.
Main Results:
- GICs exhibit multifaceted roles in GBM, including propagation, invasion, immune evasion, DNA repair, microenvironment remodeling, and chemotherapy resistance.
- Current understanding of GIC subpopulations and their specific functions remains incomplete.
- Dopamine receptor antagonists show promise for enhancing standard-of-care efficacy.
Conclusions:
- Further research into GIC subtypes is critical for advancing glioblastoma therapy.
- Targeting dopamine receptors represents a novel approach to overcome therapeutic resistance in GBM.
